AstraZeneca is a major international healthcare business engaged in research, development, manufacturing and marketing of prescription pharmaceuticals and supplier for healthcare services. AstraZeneca is one of the world's leading pharmaceutical companies with healthcare sales of US $29.55 billion and is a leader in gastrointestinal, cardiovascular, neuroscience, respiratory, oncology and infection product sales. AstraZeneca is listed in the Dow Jones Sustainability Index (Global) as well as the FTSE4Good Index.
Targacept is a clinical-stage biopharmaceutical company that discovers
and develops NNR Therapeutics (TM), a new class of drugs for the treatment
of central nervous system diseases and disorders. Targacept's product
candidates selectively modulate neuronal nicotinic receptors that serve as
key regulators of the nervous system to promote therapeutic effects and
limit adverse side effects. Targacept has product candidates in development
for Alzheimer's disease, cognitive dysfunction in schizophrenia, pain and
major depressive disorder, as well as multiple preclinical programs.
Targacept also has a cognition-focused collaboration with AstraZeneca and a
strategic alliance with GlaxoSmithKline. Targacept's news releases are
available on its website at
Copyright©2008 PR Newswire.
All rights reserved